147 related articles for article (PubMed ID: 16961440)
41. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS).
Friedman DS; Quigley HA; Gelb L; Tan J; Margolis J; Shah SN; Kim EE; Zimmerman T; Hahn SR
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5052-7. PubMed ID: 17962457
[TBL] [Abstract][Full Text] [Related]
42. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
43. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study.
Quigley HA; Friedman DS; Hahn SR
Ophthalmology; 2007 Sep; 114(9):1599-606. PubMed ID: 17572498
[TBL] [Abstract][Full Text] [Related]
45. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.
Mazzaglia G; Ambrosioni E; Alacqua M; Filippi A; Sessa E; Immordino V; Borghi C; Brignoli O; Caputi AP; Cricelli C; Mantovani LG
Circulation; 2009 Oct; 120(16):1598-605. PubMed ID: 19805653
[TBL] [Abstract][Full Text] [Related]
46. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
[TBL] [Abstract][Full Text] [Related]
47. Factors associated with adherence to phosphodiesterase type 5 inhibitors for the treatment of pulmonary arterial hypertension.
Waxman A; Chen SY; Boulanger L; Watson JA; Golden G
J Med Econ; 2013; 16(2):298-306. PubMed ID: 23216015
[TBL] [Abstract][Full Text] [Related]
48. An evaluation of educational outreach to improve evidence-based prescribing in Medicaid: a cautionary tale.
Zillich AJ; Ackermann RT; Stump TE; Ambuehl RJ; Downs SM; Holmes AM; Katz B; Inui TS
J Eval Clin Pract; 2008 Oct; 14(5):854-60. PubMed ID: 19018918
[TBL] [Abstract][Full Text] [Related]
49. Copayment reductions generate greater medication adherence in targeted patients.
Maciejewski ML; Farley JF; Parker J; Wansink D
Health Aff (Millwood); 2010 Nov; 29(11):2002-8. PubMed ID: 21041739
[TBL] [Abstract][Full Text] [Related]
50. Association of copayment and statin adherence stratified by socioeconomic status.
Kazerooni R; Bounthavong M; Watanabe JH
Ann Pharmacother; 2013 Nov; 47(11):1463-70. PubMed ID: 24259605
[TBL] [Abstract][Full Text] [Related]
51. Cost sharing, benefit design, and adherence: the case of multiple sclerosis.
Dor A; Lage MJ; Tarrants ML; Castelli-Haley J
Adv Health Econ Health Serv Res; 2010; 22():175-93. PubMed ID: 20575233
[TBL] [Abstract][Full Text] [Related]
52. Copayments for medications. Interim final rule.
Department of Veterans Affairs
Fed Regist; 2009 Dec; 74(250):69283-5. PubMed ID: 20169681
[TBL] [Abstract][Full Text] [Related]
53. Would elimination of copayments for phototherapy decrease the cost of treating psoriasis with systemic biologics? A cost analysis.
Simpson JF; Yelverton CB; Balkrishnan R; Fleischer A; Lide W; Feldman SR
Manag Care Interface; 2006 Jun; 19(6):39-43. PubMed ID: 16892660
[TBL] [Abstract][Full Text] [Related]
54. Association of copayment and socioeconomic status with hormonal contraceptive adherence in a female veteran population.
Kazerooni R; Vu K; Takizawa A; Broadhead C; Morreale AP
Womens Health Issues; 2014; 24(2):e237-41. PubMed ID: 24533983
[TBL] [Abstract][Full Text] [Related]
55. Cost-sharing and adherence to antihypertensives for low and high adherers.
Yoon J; Ettner SL
Am J Manag Care; 2009 Nov; 15(11):833-40. PubMed ID: 19895188
[TBL] [Abstract][Full Text] [Related]
56. The Relationship Between Prescription Copayments and Contraceptive Adherence in a New-user Cohort.
Marshall C; Schmittdiel J; Chandra M; Calhoun A; Raine-Bennett T
Med Care; 2018 Jul; 56(7):577-582. PubMed ID: 29847539
[TBL] [Abstract][Full Text] [Related]
57. Copayments for prescription medicines on a public health insurance scheme in Ireland.
Sinnott SJ; Normand C; Byrne S; Woods N; Whelton H
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):695-704. PubMed ID: 26696242
[TBL] [Abstract][Full Text] [Related]
58. The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.
Chin AL; Bentley JP; Pollom EL
Cancer; 2019 Feb; 125(3):374-381. PubMed ID: 30566762
[TBL] [Abstract][Full Text] [Related]
59. Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia.
Seaman KL; Sanfilippo FM; Roughead EE; Bulsara MK; Kemp-Casey A; Bulsara C; Watts GF; Preen D
BMJ Open; 2017 Jun; 7(6):e013691. PubMed ID: 28637723
[TBL] [Abstract][Full Text] [Related]
60. The international generalisability of evidence for health policy: A cross country comparison of medication adherence following policy change.
Sinnott SJ; Whelton H; Franklin JM; Polinski JM
Health Policy; 2017 Jan; 121(1):27-34. PubMed ID: 27916432
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
